🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ASCO & ACCC are supporting oncology research sites that want to establish evidence-based practical strategies to increase participation of underrepresented racial & ethnic groups in cancer treatment trials. Apply by 06.11: accc-cancer.org/home/learn/res… #clinicaltrials #cancer #ASCO21

A Transformed World Addresses Meaningful Changes in Trial Access - remarks from session chair Dr Lola Fashoyin-Aje of #FDAOncology at #ASCO21 Education session #OCEProjectEquity dailynews.ascopubs.org/do/10.1200/ADN…

New online! FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib - via The Oncologist. First author Dr. May Tun Saung, last author Dr Lola Fashoyin-Aje bit.ly/3xaO8ix

Starting our next round of 25 for 25, we're pleased to be honoring FDA Oncology Director Richard Pazdur! A decades-long oncologist & civil servant, he has dedicated his life & career to helping cancer patients. Click here to learn more about this spotlight trib.al/zxnxVgP

#FDAOncology joins the rest of the HHS family in supporting health equity for all. #Pride2021 #OCEProjectEquity

Making cancer research more inclusive - perspective by Dr. John Carpten @KeckMedUSC, #FDAOncology's Dr Lola Fashoyin-Aje, Dr. Levi Garraway Genentech and Dr. Rob Winn VCU Massey Comprehensive Cancer Center - via Nature Reviews Cancer #diversity #MedEd #inclusion #clinicaltrials rdcu.be/cnpB4

Yesterday, OCE Director Richard Pazdur, MD, welcomed the 2021 OCE Summer Scholars to our 3-week virtual program that aims to inform diverse high school juniors and seniors about oncology drug development and the role of the FDA and the Oncology Center of Excellence.

Join us July 29 for #ConversationsOnCancer: Advancing Equity in Asian American and Pacific Islander Communities - #Racism and #Injustice - 2 pm Eastern - virtual. #AAPI #cancer #equity fdaoce.formstack.com/forms/ocecoca0…

FDA approved ivosidenib (Tibsovo, Servier) for adults w/previously treated locally advanced/metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved test. FDA also approved the Oncomine Dx Target Test (Life Technologies) as a CDx bit.ly/2WptEFZ

Treatment of Older Adults with Cancer - Addressing Gaps in Evidence, by @bertagnollimm and Harpreet Singh, MD in NEJM. bit.ly/2Z1qJEH

Making cancer research more inclusive- a perspective by Dr John Carpten @KeckMedUSC #FDAOncology's Dr Lola Fashoyin-Aje Dr Levi Garraway Genentech & Dr. Rob Winn VCU Massey Comprehensive Cancer Center - Nature Reviews Cancer #diversity #MedEd #inclusion #clinicaltrials #ProjectEquity rdcu.be/cyjNt

The Drug-Dosing Conundrum in Oncology—When Less Is More. Drs. Mirat Shah, Atiqur Rahman, Marc Theoret & Rick Pazdur- via NEJM nejm.org/doi/full/10.10…

Moving on #Equity: OCE Expands #Diversity Initiative is the topic of an #FDA Oncology Center of Excellence public panel discussion under President Biden's #CancerMoonshot initiative, on May 4 at 11am Eastern. #OCEProjectEquity #OCEProjectCommunity youtu.be/8k1BMF31fLU

Thank you to our panelists for the Cancer Cabinet Community Conversation on FDA's guidance on diversity plans for clinical trials. And kudos to White House Office of Science & Technology Policy & President Donald J. Trump for the #CancerMoonshot initiative. #OCEProjectEquity #OCEProjectCommunity Watch: youtu.be/8k1BMF31fLU

#FDAOncology perspective: The On- and Off-Ramps of Oncology Accelerated Approval - via NEJM by Dr Lola Fashoyin-Aje Gautam Mehta, MD Julia Beaver Rick Pazdur nejm.org/doi/full/10.10…

OCE has 4 funding opportunities for applied regulatory science research in oncology! Applications are due over the next 3 months. If you miss the LOI deadline, no worries! You can still submit an application. Read this 🧵 thread for the links and deadlines. #OCESciCollab

#FDA #RFA for Applied Regulatory Science Research to Understand Factors that Affect the Safety and Efficacy of Underrepresented Populations in Oncology Therapeutic Development (U01) cooperative agreements. LOI due 1/6! Applications due 2/22 grants.nih.gov/grants/guide/r…

LOI due today, applications due 2/22: #FDA #RFA for Applied Regulatory Science Research to Understand Factors that Affect the Safety and Efficacy of Underrepresented Populations in Oncology Therapeutic Development (U01) cooperative agreements. grants.nih.gov/grants/guide/r…

FDA recognizes #RareDiseaseWeek by being part of #LightUpForRare. Join us today for #FDARareDiseaseDay to explore ways to engage and collaborate with patients and their advocates to support medical product development and regulation. fda.gov/news-events/fd…

Just published— Read the related paper by Dr Lola Fashoyin-Aje, Rick Pazdur et al. aacrjournals.org/clincancerres/…